Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy

NCT00006227 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT00006227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
November 20, 2000
Completion date
July 16, 2016
Enrollment
31 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

adult type ovarian granulosa cell tumor, ovarian gynandroblastoma, ovarian sertoli-leydig cell tumor, ovarian sex cord tumor with annular tubules, ovarian steroid cell tumor